Eli Lilly And Co vs Vanguard High Dividend Yield ETF — how do they compare? Eli Lilly And Co trades at $1,140.22 (market cap $1.02T), while Vanguard High Dividend Yield ETF trades at $160. The key difference: Eli Lilly And Co pays a 0.6% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals.
| LLY | VYM | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | — |
52-Week High | $1.24K | $161.17 |
52-Week Low | $625.65 | $132.90 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
VYM trades at $159.41, down 0.47% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds $94.6 billion in assets, emphasizing high dividend yield from U.S. large-cap stocks. Recent news highlights institutional buying and its role in retirement income strategies, with a dividend of $0.98 scheduled for June 2026.
Outlook remains positive for income-focused investors due to broad diversification and low costs, though risks include interest rate sensitivity and market volatility. The ETF's appeal lies in steady cash flow, but competition from higher-yielding funds poses a challenge to outperformance.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →